Menu

Recent Interviews

Andrew Davidson, CEO, Royal Helium Limited

Andrew Davidson
CEO | Royal Helium Limited
224, 4th Avenue South, S7K 5M5 Saskatoon (CAN)

davidson@royalheliumltd.com

+1 (306) 281-9104

Royal Helium CEO Andrew Davidson on NASA, SpaceX and the path to dynamic growth


Craig Taylor, CEO, Defense Metals

Craig Taylor
CEO | Defense Metals
605-815 Hornby St., V6Z 1T9 Vancouver (CAN)

craig@defensemetals.com

+1 (778) 994 8072

Milestones, ESG as an USP and the new openness of policy toward rare earths outside China - Defense Metals provides backgrounds


Alex Kent, Managing Director, Aspermont Limited

Alex Kent
Managing Director | Aspermont Limited
613 - 619 Wellington Street, WA, 6000 Perth (AUS)

Corporate@aspermont.com

+61 8 6263 9100

Aspermont shows the success of digitalization - Alex Kent has an agenda


15. July 2020 | 12:23 CET

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis
Photo credits: pixabay.com

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Legalization in the USA is expected

Medical cannabis is already legalized in 33 states in the USA and thus about 221 million people, about 67% of the total US population, have access to the natural substance. Fifty years ago, only about 12% of US citizens were in favor of legalizing marijuana, but since then the popularity has grown to 66%.

In addition, the racism debate in the USA also plays a role in the legalization issue, because around 80% of arrests involving marijuana affect people with dark skin. For this reason, experts assume that a legalization of cannabis at the federal level will take place within the next two years - detached from the outcome of the elections in November 2020.

Recovery of the cannabis industry expected

In the tailwind of a legalization in the USA and the increasing use of cannabis in medicine, EXMceuticals and XPhyto will also grow. Both companies are active in the cannabis sector and thus part of the expanding eco-system of products, therapies and suppliers. The quality and individuality will become increasingly important.

For this reason, it can be worthwhile to focus more on smaller companies than on the big players who try to cover the whole value chain with a lot of money. Usually too much complexity leads to inefficiency. Therefore, focused niche players can have an advantage.

Vaccine can slow down Covid-19

BioNTech also focuses on individuality, as the company is working on the development of individualized options for the treatment of cancer. In addition, the biotech company is currently working with Pfizer on the development of a vaccine against Covid-19 in order to be able to limit the spread of the pandemic. In view of the fact that new hotspots of spread are constantly emerging worldwide, the global demand for a vaccine is correspondingly high.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

19. May 2020 | 15:02 CET | by Mario Hose

Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!

  • Cannabis

The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.

Read

23. March 2020 | 15:00 CET | by Mario Hose

Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona

  • Cannabis

The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.

Read